APO Research
Talk to an analyst

APO RESEARCH · REPORT

Short-acting Insulin

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Short-acting Insulin Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchShort-acting Insulin Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Short-acting Insulin Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Short-acting Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Short-acting Insulin Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Short-acting Insulin Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Short-acting Insulin market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Short-acting Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Short-acting Insulin market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Short-acting Insulin market include Zhuhai United Pharmaceutical, Wanbang Biopharmaceuticals, Sinovac Biotech, HTBT, Tonghua Dongbao Pharmaceutical, Wockhardt, Sanofi, Pfizer and Novo Nordisk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Short-acting Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Short-acting Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Short-acting Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Short-acting Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Short-acting Insulin Segment by Company

Zhuhai United Pharmaceutical

Wanbang Biopharmaceuticals

Sinovac Biotech

HTBT

Tonghua Dongbao Pharmaceutical

Wockhardt

Sanofi

Pfizer

Novo Nordisk

Eli Lilly

Biocon Biologics

Bayer

BASF

Abbott Laboratories

Short-acting Insulin Segment by Type

Regular Insulin

Biosynthetic Human Insulin

Recombinant Human Insulin

Other

Short-acting Insulin Segment by Application

Type 2 Diabetes

Type 1 Diabetes

Gestational Diabetes

Complications of Diabetes

Other

Short-acting Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Short-acting Insulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Short-acting Insulin market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Short-acting Insulin significant trends, drivers, influence factors in global and regions.

6. To analyze Short-acting Insulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Short-acting Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Short-acting Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Short-acting Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Short-acting Insulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Short-acting Insulin industry.

Chapter 3: Detailed analysis of Short-acting Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Short-acting Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Short-acting Insulin in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Short-acting Insulin Industry Trends Table 2. Short-acting Insulin Industry Drivers Table 3. Short-acting Insulin Industry Opportunities and Challenges Table 4. Short-acting Insulin Industry Restraints Table 5. Global Short-acting Insulin Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Short-acting Insulin Revenue Share by Company (2021-2026) Table 7. Global Short-acting Insulin Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Short-acting Insulin Sales Volume Share by Company (2021-2026) Table 9. Global Short-acting Insulin Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Short-acting Insulin Company Ranking, (2024-2026) & (USD Million) Table 11. Global Short-acting Insulin Key Company Manufacturing Base & Headquarters Table 12. Global Short-acting Insulin Company, Product Type & Application Table 13. Global Short-acting Insulin Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Short-acting Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Regular Insulin Table 18. Significant Companies of Biosynthetic Human Insulin Table 19. Significant Companies of Recombinant Human Insulin Table 20. Significant Companies of Other Table 21. Global Short-acting Insulin Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Short-acting Insulin Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Short-acting Insulin Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Short-acting Insulin Sales Volume Share by Type (2021-2026) Table 25. Global Short-acting Insulin Sales Volume Share by Type (2027-2032) Table 26. Global Short-acting Insulin Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Short-acting Insulin Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Short-acting Insulin Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Short-acting Insulin Sales Value Share by Type (2021-2026) Table 30. Global Short-acting Insulin Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Type 2 Diabetes Table 32. Significant Companies of Type 1 Diabetes Table 33. Significant Companies of Gestational Diabetes Table 34. Significant Companies of Complications of Diabetes Table 35. Significant Companies of Other Table 36. Global Short-acting Insulin Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Short-acting Insulin Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Short-acting Insulin Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Short-acting Insulin Sales Volume Share by Application (2021-2026) Table 40. Global Short-acting Insulin Sales Volume Share by Application (2027-2032) Table 41. Global Short-acting Insulin Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Short-acting Insulin Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Short-acting Insulin Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Short-acting Insulin Sales Value Share by Application (2021-2026) Table 45. Global Short-acting Insulin Sales Value Share by Application (2027-2032) Table 46. Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Short-acting Insulin Sales by Region (2021-2026) & (K Units) Table 48. Global Short-acting Insulin Sales Market Share by Region (2021-2026) Table 49. Global Short-acting Insulin Sales by Region (2027-2032) & (K Units) Table 50. Global Short-acting Insulin Sales Market Share by Region (2027-2032) Table 51. Global Short-acting Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Short-acting Insulin Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Short-acting Insulin Sales Value Share by Region (2021-2026) Table 54. Global Short-acting Insulin Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Short-acting Insulin Sales Value Share by Region (2027-2032) Table 56. Global Short-acting Insulin Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Short-acting Insulin Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Short-acting Insulin Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Short-acting Insulin Sales by Country (2021-2026) & (K Units) Table 61. Global Short-acting Insulin Sales Market Share by Country (2021-2026) Table 62. Global Short-acting Insulin Sales by Country (2027-2032) & (K Units) Table 63. Global Short-acting Insulin Sales Market Share by Country (2027-2032) Table 64. Global Short-acting Insulin Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Short-acting Insulin Sales Value Market Share by Country (2021-2026) Table 66. Global Short-acting Insulin Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Short-acting Insulin Sales Value Market Share by Country (2027-2032) Table 68. Zhuhai United Pharmaceutical Company Information Table 69. Zhuhai United Pharmaceutical Business Overview Table 70. Zhuhai United Pharmaceutical Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio Table 72. Zhuhai United Pharmaceutical Recent Development Table 73. Wanbang Biopharmaceuticals Company Information Table 74. Wanbang Biopharmaceuticals Business Overview Table 75. Wanbang Biopharmaceuticals Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio Table 77. Wanbang Biopharmaceuticals Recent Development Table 78. Sinovac Biotech Company Information Table 79. Sinovac Biotech Business Overview Table 80. Sinovac Biotech Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sinovac Biotech Short-acting Insulin Product Portfolio Table 82. Sinovac Biotech Recent Development Table 83. HTBT Company Information Table 84. HTBT Business Overview Table 85. HTBT Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. HTBT Short-acting Insulin Product Portfolio Table 87. HTBT Recent Development Table 88. Tonghua Dongbao Pharmaceutical Company Information Table 89. Tonghua Dongbao Pharmaceutical Business Overview Table 90. Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio Table 92. Tonghua Dongbao Pharmaceutical Recent Development Table 93. Wockhardt Company Information Table 94. Wockhardt Business Overview Table 95. Wockhardt Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Wockhardt Short-acting Insulin Product Portfolio Table 97. Wockhardt Recent Development Table 98. Sanofi Company Information Table 99. Sanofi Business Overview Table 100. Sanofi Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Sanofi Short-acting Insulin Product Portfolio Table 102. Sanofi Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Short-acting Insulin Product Portfolio Table 107. Pfizer Recent Development Table 108. Novo Nordisk Company Information Table 109. Novo Nordisk Business Overview Table 110. Novo Nordisk Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Novo Nordisk Short-acting Insulin Product Portfolio Table 112. Novo Nordisk Recent Development Table 113. Eli Lilly Company Information Table 114. Eli Lilly Business Overview Table 115. Eli Lilly Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Eli Lilly Short-acting Insulin Product Portfolio Table 117. Eli Lilly Recent Development Table 118. Biocon Biologics Company Information Table 119. Biocon Biologics Business Overview Table 120. Biocon Biologics Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Biocon Biologics Short-acting Insulin Product Portfolio Table 122. Biocon Biologics Recent Development Table 123. Bayer Company Information Table 124. Bayer Business Overview Table 125. Bayer Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Bayer Short-acting Insulin Product Portfolio Table 127. Bayer Recent Development Table 128. BASF Company Information Table 129. BASF Business Overview Table 130. BASF Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. BASF Short-acting Insulin Product Portfolio Table 132. BASF Recent Development Table 133. Abbott Laboratories Company Information Table 134. Abbott Laboratories Business Overview Table 135. Abbott Laboratories Short-acting Insulin Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Abbott Laboratories Short-acting Insulin Product Portfolio Table 137. Abbott Laboratories Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Short-acting Insulin Distributors List Table 141. Short-acting Insulin Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Short-acting Insulin Product Image Figure 2. Global Short-acting Insulin Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 4. Global Short-acting Insulin Sales (2021-2032) & (K Units) Figure 5. Global Short-acting Insulin Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Short-acting Insulin Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Regular Insulin Image Figure 10. Biosynthetic Human Insulin Image Figure 11. Recombinant Human Insulin Image Figure 12. Other Image Figure 13. Global Short-acting Insulin Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Short-acting Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Short-acting Insulin Sales Volume Share by Type (2021-2032) Figure 16. Global Short-acting Insulin Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Short-acting Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Short-acting Insulin Sales Value Share by Type (2021-2032) Figure 19. Type 2 Diabetes Image Figure 20. Type 1 Diabetes Image Figure 21. Gestational Diabetes Image Figure 22. Complications of Diabetes Image Figure 23. Other Image Figure 24. Global Short-acting Insulin Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Short-acting Insulin Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Short-acting Insulin Sales Volume Share by Application (2021-2032) Figure 27. Global Short-acting Insulin Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Short-acting Insulin Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Short-acting Insulin Sales Value Share by Application (2021-2032) Figure 30. Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Short-acting Insulin Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Short-acting Insulin Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Short-acting Insulin Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 35. North America Short-acting Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Short-acting Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Short-acting Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 41. South America Short-acting Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Short-acting Insulin Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Short-acting Insulin Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Short-acting Insulin Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Short-acting Insulin Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Short-acting Insulin Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Short-acting Insulin Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Short-acting Insulin Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Regular Insulin
  • Biosynthetic Human Insulin
  • Recombinant Human Insulin
  • Other
Applications
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Gestational Diabetes
  • Complications of Diabetes
  • Other
Companies covered
  • Zhuhai United Pharmaceutical
  • Wanbang Biopharmaceuticals
  • Sinovac Biotech
  • HTBT
  • Tonghua Dongbao Pharmaceutical
  • Wockhardt
  • Sanofi
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Biocon Biologics
  • Bayer
  • BASF
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Short-acting Insulin Sales Value (2021-2032)
  4. 1.2.2 Global Short-acting Insulin Sales Volume (2021-2032)
  5. 1.2.3 Global Short-acting Insulin Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Short-acting Insulin Market Dynamics
  1. 2.1 Short-acting Insulin Industry Trends
  2. 2.2 Short-acting Insulin Industry Drivers
  3. 2.3 Short-acting Insulin Industry Opportunities and Challenges
  4. 2.4 Short-acting Insulin Industry Restraints
3 Short-acting Insulin Market by Company
  1. 3.1 Global Short-acting Insulin Company Revenue Ranking in 2025
  2. 3.2 Global Short-acting Insulin Revenue by Company (2021-2026)
  3. 3.3 Global Short-acting Insulin Sales Volume by Company (2021-2026)
  4. 3.4 Global Short-acting Insulin Average Price by Company (2021-2026)
  5. 3.5 Global Short-acting Insulin Company Ranking (2024-2026)
  6. 3.6 Global Short-acting Insulin Company Manufacturing Base and Headquarters
  7. 3.7 Global Short-acting Insulin Company Product Type and Application
  8. 3.8 Global Short-acting Insulin Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Short-acting Insulin Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Short-acting Insulin Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Short-acting Insulin Market by Type
  1. 4.1 Short-acting Insulin Type Introduction
  2. 4.1.1 Regular Insulin
  3. 4.1.2 Biosynthetic Human Insulin
  4. 4.1.3 Recombinant Human Insulin
  5. 4.1.4 Other
  6. 4.2 Global Short-acting Insulin Sales Volume by Type
  7. 4.2.1 Global Short-acting Insulin Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Short-acting Insulin Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Short-acting Insulin Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Short-acting Insulin Sales Value by Type
  11. 4.3.1 Global Short-acting Insulin Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Short-acting Insulin Sales Value by Type (2021-2032)
  13. 4.3.3 Global Short-acting Insulin Sales Value Share by Type (2021-2032)
5 Short-acting Insulin Market by Application
  1. 5.1 Short-acting Insulin Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Type 1 Diabetes
  4. 5.1.3 Gestational Diabetes
  5. 5.1.4 Complications of Diabetes
  6. 5.1.5 Other
  7. 5.2 Global Short-acting Insulin Sales Volume by Application
  8. 5.2.1 Global Short-acting Insulin Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Short-acting Insulin Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Short-acting Insulin Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Short-acting Insulin Sales Value by Application
  12. 5.3.1 Global Short-acting Insulin Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Short-acting Insulin Sales Value by Application (2021-2032)
  14. 5.3.3 Global Short-acting Insulin Sales Value Share by Application (2021-2032)
6 Short-acting Insulin Regional Sales and Value Analysis
  1. 6.1 Global Short-acting Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Short-acting Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Short-acting Insulin Sales by Region: 2021-2026
  4. 6.2.2 Global Short-acting Insulin Sales by Region (2027-2032)
  5. 6.3 Global Short-acting Insulin Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Short-acting Insulin Sales Value by Region (2021-2032)
  7. 6.4.1 Global Short-acting Insulin Sales Value by Region: 2021-2026
  8. 6.4.2 Global Short-acting Insulin Sales Value by Region (2027-2032)
  9. 6.5 Global Short-acting Insulin Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Short-acting Insulin Sales Value (2021-2032)
  12. 6.6.2 North America Short-acting Insulin Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Short-acting Insulin Sales Value (2021-2032)
  15. 6.7.2 Europe Short-acting Insulin Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Short-acting Insulin Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Short-acting Insulin Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Short-acting Insulin Sales Value (2021-2032)
  21. 6.9.2 South America Short-acting Insulin Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Short-acting Insulin Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Short-acting Insulin Sales Value Share by Country, 2025 VS 2032
7 Short-acting Insulin Country-level Sales and Value Analysis
  1. 7.1 Global Short-acting Insulin Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Short-acting Insulin Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Short-acting Insulin Sales by Country (2021-2032)
  4. 7.3.1 Global Short-acting Insulin Sales by Country (2021-2026)
  5. 7.3.2 Global Short-acting Insulin Sales by Country (2027-2032)
  6. 7.4 Global Short-acting Insulin Sales Value by Country (2021-2032)
  7. 7.4.1 Global Short-acting Insulin Sales Value by Country (2021-2026)
  8. 7.4.2 Global Short-acting Insulin Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Short-acting Insulin Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Short-acting Insulin Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Short-acting Insulin Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Short-acting Insulin Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Short-acting Insulin Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Short-acting Insulin Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Short-acting Insulin Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Short-acting Insulin Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Short-acting Insulin Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Short-acting Insulin Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Short-acting Insulin Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Short-acting Insulin Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Short-acting Insulin Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Short-acting Insulin Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Short-acting Insulin Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Short-acting Insulin Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Short-acting Insulin Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Short-acting Insulin Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Short-acting Insulin Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Short-acting Insulin Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Short-acting Insulin Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Short-acting Insulin Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Short-acting Insulin Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Short-acting Insulin Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Short-acting Insulin Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Short-acting Insulin Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Short-acting Insulin Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Short-acting Insulin Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Short-acting Insulin Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Short-acting Insulin Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai United Pharmaceutical
  2. 8.1.1 Zhuhai United Pharmaceutical Company Information
  3. 8.1.2 Zhuhai United Pharmaceutical Business Overview
  4. 8.1.3 Zhuhai United Pharmaceutical Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai United Pharmaceutical Short-acting Insulin Product Portfolio
  6. 8.1.5 Zhuhai United Pharmaceutical Recent Developments
  7. 8.2 Wanbang Biopharmaceuticals
  8. 8.2.1 Wanbang Biopharmaceuticals Company Information
  9. 8.2.2 Wanbang Biopharmaceuticals Business Overview
  10. 8.2.3 Wanbang Biopharmaceuticals Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Wanbang Biopharmaceuticals Short-acting Insulin Product Portfolio
  12. 8.2.5 Wanbang Biopharmaceuticals Recent Developments
  13. 8.3 Sinovac Biotech
  14. 8.3.1 Sinovac Biotech Company Information
  15. 8.3.2 Sinovac Biotech Business Overview
  16. 8.3.3 Sinovac Biotech Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sinovac Biotech Short-acting Insulin Product Portfolio
  18. 8.3.5 Sinovac Biotech Recent Developments
  19. 8.4 HTBT
  20. 8.4.1 HTBT Company Information
  21. 8.4.2 HTBT Business Overview
  22. 8.4.3 HTBT Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 HTBT Short-acting Insulin Product Portfolio
  24. 8.4.5 HTBT Recent Developments
  25. 8.5 Tonghua Dongbao Pharmaceutical
  26. 8.5.1 Tonghua Dongbao Pharmaceutical Company Information
  27. 8.5.2 Tonghua Dongbao Pharmaceutical Business Overview
  28. 8.5.3 Tonghua Dongbao Pharmaceutical Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Tonghua Dongbao Pharmaceutical Short-acting Insulin Product Portfolio
  30. 8.5.5 Tonghua Dongbao Pharmaceutical Recent Developments
  31. 8.6 Wockhardt
  32. 8.6.1 Wockhardt Company Information
  33. 8.6.2 Wockhardt Business Overview
  34. 8.6.3 Wockhardt Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Wockhardt Short-acting Insulin Product Portfolio
  36. 8.6.5 Wockhardt Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Short-acting Insulin Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Short-acting Insulin Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Novo Nordisk
  50. 8.9.1 Novo Nordisk Company Information
  51. 8.9.2 Novo Nordisk Business Overview
  52. 8.9.3 Novo Nordisk Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Novo Nordisk Short-acting Insulin Product Portfolio
  54. 8.9.5 Novo Nordisk Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Short-acting Insulin Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Biocon Biologics
  62. 8.11.1 Biocon Biologics Company Information
  63. 8.11.2 Biocon Biologics Business Overview
  64. 8.11.3 Biocon Biologics Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biocon Biologics Short-acting Insulin Product Portfolio
  66. 8.11.5 Biocon Biologics Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Short-acting Insulin Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 BASF
  74. 8.13.1 BASF Company Information
  75. 8.13.2 BASF Business Overview
  76. 8.13.3 BASF Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 BASF Short-acting Insulin Product Portfolio
  78. 8.13.5 BASF Recent Developments
  79. 8.14 Abbott Laboratories
  80. 8.14.1 Abbott Laboratories Company Information
  81. 8.14.2 Abbott Laboratories Business Overview
  82. 8.14.3 Abbott Laboratories Short-acting Insulin Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Abbott Laboratories Short-acting Insulin Product Portfolio
  84. 8.14.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Short-acting Insulin Value Chain Analysis
  2. 9.1.1 Short-acting Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Short-acting Insulin Sales Mode & Process
  6. 9.2 Short-acting Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Short-acting Insulin Distributors
  9. 9.2.3 Short-acting Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst